Seres Therapeutics, Inc. (MCRB)
Seres Therapeutics, Inc. is a biotechnology company focused on developing microbiome-based therapeutics. The company utilizes its proprietary platform to discover, develop, and commercialize biologic products that modulate the human microbiome to treat various diseases, including those related to gastrointestinal health. Founded in 2014 and headquartered in Cambridge, Massachusetts, Seres aims to address unmet medical needs through innovative microbiome science.
Company News
Denodo, a leader in data management, has announced the Denodo University Challenge, 'Data and AI for Real-World Impact', which aims to encourage students to develop innovative AI-driven solutions that have a demonstrable impact on social and economic challenges. The challenge will leverage Denodo's data management and AI tools, including the Deno...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Morgan Stanley boosted the price target for Sea Limited (NYSE: SE) from $47 to $65. Morgan Stanley analyst Mark Goodridge maintained an Equal-Weight rating....
Halozyme Therapeutics (HALO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Seres's FDA-approved Vowst faces commercial challenges despite clinical success, impacting financials. Read why I downgrade MCRB stock to a strong sell.
Penny stocks to watch with big news this week. The post Best Penny Stocks To Buy? 5 With Big News This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.